Advanced Search
YIN Lei, WANG Ying, CHEN Song, GAO Xiangdong. Advances of glucagon-like peptide-1 receptor agonists in the treatment of nervous system diseases[J]. Journal of China Pharmaceutical University, 2014, 45(4): 383-391. DOI: 10.11665/j.issn.1000-5048.20140401
Citation: YIN Lei, WANG Ying, CHEN Song, GAO Xiangdong. Advances of glucagon-like peptide-1 receptor agonists in the treatment of nervous system diseases[J]. Journal of China Pharmaceutical University, 2014, 45(4): 383-391. DOI: 10.11665/j.issn.1000-5048.20140401
shu

Advances of glucagon-like peptide-1 receptor agonists in the treatment of nervous system diseases

    Graphical Abstract
    • Abstract
  • The novel incretin-based diabetic drug, glucagon like peptide-1(GLP-1), has a range of physiological effects. The widespread distribution of GLP-1 receptors also determines the pleiotropy of GLP-1 receptor agonists. Recent studies suggest that, in addition to anti-diabetic use, GLP-1 receptor agonists exert neuroprotective and anti-inflammatory effects in both central and peripheral nervous systems. Therefore, GLP-1 receptor agonists show great potential as novel preventive or therapeutic agents for neurodegenerative conditions. This article mainly reviews the recent pre-clinical and clinical studies about GLP-1 receptor agonists applied in Alzheimer′s disease, Parkinson′s disease, stroke and other neurological diseases.
    • FullText(HTML)
  • loading
    • References (39)
    • Related Articles

Catalog

    Turn off MathJax
    Article Contents

    Total visits：

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return